Literature DB >> 15548361

Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer.

Regine Schneider-Stock1, Carsten Boltze, Brigitte Peters, Reinhard Szibor, Olfert Landt, Frank Meyer, Albert Roessner.   

Abstract

According to recent reports, some cancer types exhibit nonrandom allele loss at codon 72 in exon 4 of the p53 gene [coding for proline (72Pro) or arginine (72Arg)]. To clarify this phenomenon for colorectal cancer and to find out if this preferential loss might have any functional significance, p53 loss of heterozygosity (LOH) and p53 mutations were investigated in a group of 61 colorectal cancers and 28 liver metastases, and were correlated with clinicopathologic factors. A comparison of a patient's blood codon 72 status with a healthy control group did not reveal an enhanced risk of developing colorectal tumors for one of the two isoforms. p53-LOH and p53 mutations were found in 62.2% and 39.4% of primary tumors, respectively, and in 57.9% and 25% of hepatic metastases, respectively. In 14 heterozygous cases showing exon 4-LOH, only the 72Pro allele was lost and the retained 72Arg was preferentially mutated. In general, p53 mutations were significantly associated with the 72Arg tumor status (P < .001). Distal tumors showed allelic losses of the p53 gene more commonly than proximal tumors (P = .054). The prevalence of 72Arg increased in frequency with higher Dukes stage (P = .056). We suggest that either the preferential loss of 72Pro or the mutation of the 72Arg in colorectal cancer and hepatic metastases is associated with malignant potential and might reflect carcinogenic exposure, particularly in the distal part of the large intestines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15548361      PMCID: PMC1531656          DOI: 10.1593/neo.04178

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  36 in total

1.  Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus.

Authors:  L A Brooks; J A Tidy; B Gusterson; L Hiller; J O'Nions; M Gasco; M C Marin; P J Farrell; W G Kaelin; T Crook
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

2.  Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants.

Authors:  M Tada; K Furuuchi; M Kaneda; J Matsumoto; M Takahashi; A Hirai; Y Mitsumoto; R D Iggo; T Moriuchi
Journal:  Carcinogenesis       Date:  2001-03       Impact factor: 4.944

3.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer.

Authors:  T Watanabe; T T Wu; P J Catalano; T Ueki; R Satriano; D G Haller; A B Benson; S R Hamilton
Journal:  N Engl J Med       Date:  2001-04-19       Impact factor: 91.245

4.  p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract.

Authors:  Mutsuo Furihata; Tamotsu Takeuchi; Manabu Matsumoto; Atsushi Kurabayashi; Yuji Ohtsuki; Naotami Terao; Morimasa Kuwahara; Taro Shuin
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

5.  The p53 codon 72 polymorphism and lung cancer risk.

Authors:  R Fan; M T Wu; D Miller; J C Wain; K T Kelsey; J K Wiencke; D C Christiani
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-10       Impact factor: 4.254

Review 6.  Different mechanisms in the tumorigenesis of proximal and distal colon cancers.

Authors:  A Lindblom
Journal:  Curr Opin Oncol       Date:  2001-01       Impact factor: 3.645

7.  p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development.

Authors:  I Zehbe; G Voglino; E Wilander; H Delius; A Marongiu; L Edler; F Klimek; S Andersson; M Tommasino
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

8.  Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years.

Authors:  Shan Wang-Gohrke; Heiko Becher; Rolf Kreienberg; Ingo B Runnebaum; Jenny Chang-Claude
Journal:  Pharmacogenetics       Date:  2002-04

9.  Mutations and allelic loss of p53 in primary tumor DNA from potentially cured patients with colorectal carcinoma.

Authors:  A Forslund; C Lönnroth; M Andersson; H Brevinge; K Lundholm
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

10.  Genetic pathways in the evolution of morphologically distinct colorectal neoplasms.

Authors:  M Yashiro; J M Carethers; L Laghi; K Saito; P Slezak; E Jaramillo; C Rubio; K Koizumi; K Hirakawa; C R Boland
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

View more
  19 in total

Review 1.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

2.  TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development.

Authors:  Natalia Volodko; Mohamed Salla; Bertus Eksteen; Richard N Fedorak; Hien Q Huynh; Shairaz Baksh
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

3.  TP53 alterations and colorectal cancer predisposition in south Indian population: a case-control study.

Authors:  Gopi Krishna Singamsetty; Sravanthi Malempati; Srichandana Bhogadhi; Ravinder Kondreddy; Suresh Govatati; Naveen Kumar Tangudu; Sowdamani Govatati; Anil Kumar kuraganti; Manjula Bhanoori; Kondaiah Kassetty
Journal:  Tumour Biol       Date:  2013-10-26

4.  TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis.

Authors:  Jing-Jun Wang; Yuan Zheng; Liang Sun; Li Wang; Peng-Bo Yu; Jian-Hua Dong; Lei Zhang; Jing Xu; Wei Shi; Yu-Chun Ren
Journal:  Mol Biol Rep       Date:  2010-12-08       Impact factor: 2.316

5.  Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population.

Authors:  S Mitra; S Banerjee; C Misra; R K Singh; A Roy; A Sengupta; C K Panda; S Roychoudhury
Journal:  J Clin Pathol       Date:  2006-11-01       Impact factor: 3.411

6.  Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression.

Authors:  Zhong-Zheng Zhu; Bing Liu; Ai-Zhong Wang; Hang-Ruo Jia; Xia-Xiang Jin; Xiang-Lei He; Li-Fang Hou; Guan-Shan Zhu
Journal:  J Zhejiang Univ Sci B       Date:  2008-11       Impact factor: 3.066

7.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

Review 8.  Genetic Modifiers of the p53 Pathway.

Authors:  Subhasree Basu; Maureen E Murphy
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

9.  Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina.

Authors:  Luis Orlando Pérez; Martin Carlos Abba; Fernando Noel Dulout; Carlos Daniel Golijow
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

10.  Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.

Authors:  Ten-i Godai; Tetsuji Suda; Nobuhiro Sugano; Kazuhito Tsuchida; Manabu Shiozawa; Hironobu Sekiguchi; Akiko Sekiyama; Mitsuyo Yoshihara; Shoichi Matsukuma; Yuji Sakuma; Eiju Tsuchiya; Yoichi Kameda; Makoto Akaike; Yohei Miyagi
Journal:  BMC Cancer       Date:  2009-12-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.